Trial Profile
The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir (Primary) ; Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 03 Feb 2020 Results (N=93), analysis of the data pooled from 4 trials(3 phase I studies NCT02219217, NCT02509195 and NCT03094507 and one Phase III NCT02351908) assessing genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics, published in the Journal of Antimicrobial Chemotherapy
- 07 Mar 2019 Results (n=21) presented at the 26th Conference on Retroviruses and Opportunistic Infections.
- 01 Oct 2018 Results published in the Journal of Antimicrobial Chemotherapy